1,3-selenazol-4-one derivatives inhibit inducible nitric oxide-mediated nitric oxide production in lipopolysaccharide-induced BV-2 cells. 2003

Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
Department of Physical Pharmacy, College of Pharmacy, Seoul National University, Korea.

Activated microglia extensively produce nitric oxide (NO) by inducing expression of inducible NO synthase (iNOS). NO plays a deleterious role in brain inflammation and neuronal death. In the present study, we investigated the effects of 1,3-selenazol-4-one derivatives (Sz-A, B, C, D and E) on NO production and iNOS expression in lipopolysaccharide (LPS)-induced BV-2 cells, a murine microglia cell line. Among these compounds, Sz-B and C remarkably inhibited LPS-induced NO production relative to that of Sz-A, D, and E at 5 microM in BV-2 cells. Sz-B and C dose-dependently inhibited NO production at 1, 5, and 10 microM without toxicity to BV-2 cells. Sz-B and C also dose-dependently suppressed iNOS expression at the same concentrations in LPS-induced BV-2 cells. This result suggests that Sz-B and C inhibit iNOS-mediated NO production in LPS-induced BV-2 cells. Structurally, Sz-B and C bear an ethyl or methyl group at the 5 positions of the 4-selenazolone skeletons, which could play an important role in inhibiting iNOS-mediated NO production.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001393 Azoles Five membered rings containing a NITROGEN atom. Azole
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016566 Organoselenium Compounds Organic compounds which contain selenium as an integral part of the molecule. Compounds, Organoselenium

Related Publications

Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
May 2001, Journal of neurochemistry,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
January 2011, Biological & pharmaceutical bulletin,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
January 2010, Journal of pharmacological sciences,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
January 2003, Brain research. Molecular brain research,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
December 2010, Journal of enzyme inhibition and medicinal chemistry,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
December 2002, Chemical & pharmaceutical bulletin,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
February 2016, Journal of pharmacological sciences,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
February 2010, Toxicology letters,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
January 2005, FEMS immunology and medical microbiology,
Young-Joon Park, and Mamoru Koketsu, and Jeong Min Kim, and Joo-Hong Yeo, and Hideharu Ishihara, and Kwang-Gill Lee, and Sun Yeou Kim, and Chong-Kook Kim
January 2003, Journal of neuroscience research,
Copied contents to your clipboard!